Only 36% of employers cover GLP-1s for weight loss, flat from 2025. Many push workers to FSAs or third-party platforms. A Medicare pilot may shift cost calculus.
Alpha Score of 73 reflects strong overall profile with strong momentum, moderate value, strong quality, moderate sentiment.
Employer coverage of GLP-1 drugs for weight loss has not expanded this year, a new survey shows. The International Foundation of Employee Benefit Plans found that 36% of health plans cover the drugs for both diabetes and obesity, unchanged from 2025. Coverage for diabetes only rose to 60% from 55% last year.
Cost is the central barrier. Among surveyed employers, GLP-1 drugs accounted for 11.4% of annual pharmacy claims in 2026, up from 6.9% in 2023. Plans have responded by tightening eligibility or excluding weight loss coverage entirely.
Justin Held, IFEBP’s director of educational programs, said employers are looking for workarounds. About 27% of plans now encourage employees to obtain GLP-1s through direct-to-consumer platforms. Another 21% direct workers to use flexible spending accounts or health savings accounts for the treatments.
Many plans already offer services that could reduce the need for weight-loss drugs. Disease and chronic care management is available from 74% of employers. Nutritional counseling and bariatric surgery each cover 61% of plans. Lifestyle modification programs and non-GLP-1 obesity drugs are also common.
What could shift employer thinking is evidence that covering obesity drugs lowers overall costs. Fewer knee replacements and bariatric surgeries, higher productivity. “If those things are happening, then they might say it’s worth it,” Held said. Real-world data has not yet materialized, he added.
A Medicare demonstration project launched this year may offer the first glimpse. The 18-month program allows coverage of GLP-1s for obesity. Results could influence employer decisions.
For now, only 9% of employers surveyed said they are considering adding weight-loss coverage.
Lilly’s Zepbound competes directly with Novo Nordisk’s Wegovy. The flat employer coverage caps near-term growth for both drugs in the U.S. Lilly carries an Alpha Score of 73 out of 100, rated moderate, reflecting its strong pipeline but payer-adoption uncertainty. Details are on the LLY stock page.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.